Research and Markets: Strategic Analysis of Indian Biosimilar Market - Impending Patent Expiries Encourage Companies to Ramp up Biosimilar Manufacturing Capabilities

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/98393c/strategic_analysis) has announced the addition of Frost & Sullivan's new report "Strategic Analysis of Indian Biosimilar Market" to their offering.

This Frost & Sullivan research service titled Strategic Analysis of Indian Biosimilar Market presents a comprehensive analysis of the market through primary research, including the evaluation of market size and components, as well as market opportunities, to enable decisions related to future strategies and investments.

India Emerges as Dominant Participant in the Biosimilar Market

Impending Patent Expiries Encourage Companies to Ramp up Biosimilar Manufacturing Capabilities

The Indian biosimilar market has witnessed robust growth and the country is poised to attain a position of leadership in this space. With the introduction of insulin and erythropoietin biosimilars, India has proved its capability to be a major contributor to this market. With exceptional biosimilar manufacturers such as Wockhardt, Biocon, Dr. Reddy's, Intas Biopharmaceuticals, and many emerging participants, India is on a sure fire route to market dominance in the global biosimilar market.

Many biologics are going off-patent by 2014, providing a multi-million dollar opportunity to biosimilar manufacturing companies, notes the analyst of this research service. With the increasing number of patent expiries, Indian companies are arming themselves with biosimilar manufacturing capabilities, either in the form of joint ventures or alliances with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs).

Cost arbitrage is another prominent advantage for the Indian biosimilar industry. The manufacture and development of a biosimilar molecule requires an investment of about $10 to 20 million, as compared to $50 to 100 million in developed countries. Manufacturing in India reduces the investment by about 40 percent, enabling India to become a hub for outsourcing biosimilar manufacturing. Cost efficiency reduces the appeal for imported biosimilars and unleashes huge export potential.

Companies Mentioned:

• Biocon
• Dr Reddy's
• Ranbaxy
• Wockhardt
• Intas Pharmaceuticals
• Shantha Biotechnics

For more information visit http://www.researchandmarkets.com/research/98393c/strategic_analysis